Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 531-545

  Smith, Terika P ^a   Haymond, Tami ^a   Smith, Sherika N ^a   Sweitzer, Sarah M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN COLLEGE   (United States)

Author keywords

Acute pain; Chronic pain; Endothelin receptor antagonists; Endothelin 1

Indexed keywords

AMBRISENTAN; ATRASENTAN; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; FORMALDEHYDE; HYDROXYUREA; INTERLEUKIN 6; MORPHINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

AGE; ALLODYNIA; ANTINOCICEPTION; CANCER PAIN; CHRONIC ARTHRITIS; CHRONIC CONSTRICTION INJURY; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; CYTOKINE RELEASE; DIABETIC NEUROPATHY; DIASTOLIC HEART FAILURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERALGESIA; INFLAMMATORY PAIN; KIDNEY CANCER; LUNG FIBROSIS; MORPHINE TOLERANCE; NERVE CRUSH; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OVARY CANCER; PAIN; PERITONEUM CANCER; POSTOPERATIVE PAIN; PROSTATE CANCER; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SEX DIFFERENCE; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SPINAL GANGLION; SPINAL NERVE LIGATION INJURY; SUBARACHNOID HEMORRHAGE; TRIGEMINUS NEURALGIA; UTERINE TUBE CARCINOMA;

EID: 84908092206     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: 10.2147/JPR.S65923     Document Type: Review

References (147)

1. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl. 1988;6(4):S188-S191.
2. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46(3):325-415.
3. Giannessi D, Del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res. 2001;43(2):111-126.
4. Lalich M, McNeel DG, Wilding G, Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007;25(8):785-794.
5. Dahlöf B, Gustafsson D, Hedner T, Jern S, Hansson L. Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens. 1990;8(9):811-817.
6. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1(9):944-949.
7. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med. 1991;325(14):997-1001.
8. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191(3):823-830.
9. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 1997;96(10):3737-3744.
10. Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides. 2008;42(2):119-132.
11. Hasue F, Kuwaki T, Kisanuki YY, et al. Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice. Neuroscience. 2005;130(2):349-358.
12. Liu Y, Yamada H, Ochi J. Immunocytochemical studies on endothelin in mast cells and macrophages in the rat gastrointestinal tract. Histochem Cell Biol. 1998;109(4):301-307.
13. Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med. 1990;172(6):1741-1748.
14. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. October 15, 2006;12(20 Pt 2):6296s-6300s.
15. Ahn GY, Butt KI, Jindo T, Yaguchi H, Tsuboi R, Ogawa H. The expression of endothelin-1 and its binding sites in mouse skin increased after ultraviolet B irradiation or local injection of tumor necrosis factor alpha. J Dermatol. 1998;25(2):78-84.
16. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs. 2002;20(2):173-182.
17. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96(5):1593-1597.
18. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267(23):16066-16068.
19. Rubin SA, Levin ER. Clinical review 53: The endocrinology of vasoactive peptides: synthesis to function. J Clin Endocrinol Metab. 1994;78(1):6-10.
20. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H. Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem. 2000;275(23):17596-17604.
21. Burkhardt M, Barton M, Shaw SG. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertens. 2000;18(3):273-279.
22. Gohla A, Schultz G, Offermanns S. Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction. Circ Res. 2000;87(3):221-227.
23. Masaki T. Endothelin in vascular biology. Ann N Y Acad Sci. 1994;714(1):101-108.
24. Nicol GDET. ET - phone the pain clinic. Trends Neurosci. 2004;27(4):177-180, discussion 180.
25. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348(6303):730-732.
26. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348(6303):732-735.
27. Rashid AJ, O'Dowd BF, George SR. Minireview: Diversity and complexity of signaling through peptidergic G protein-coupled receptors. Endocrinology. 2004;145(6):2645-2652.
28. Zhou Z, Davar G, Strichartz G. Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. J Neurosci. 2002;22(15): 6325-6330.
29. Masaki T, Miwa S, Sawamura T, Ninomiya H, Okamoto Y. Subcellular mechanisms of endothelin action in vascular system. Eur J Pharmacol. 1999;375(1-3):133-138.
30. Ghoneim MA, Yamamoto T, Hirose S, Nagasawa T, Hagiwara H. Endothelium localization of ETB receptor revealed by immunohistochemistry. J Cardiovasc Pharmacol. 1993;22(Suppl 8): S111-S112.
31. Shetty SS, Okada T, Webb RL, DelGrande D, Lappe RW. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993;191(2):459-464.
32. Sakurai-Yamashita Y, Yamashita K, Yoshida A, et al. Rat peritoneal macrophages express endothelin ET(B) but not endothelin ET(A) receptors. Eur J Pharmacol. 1997;338(2):199-203.
33. Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW. Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci. 2001;21(3): 999-1006.
34. Chichorro JG, Fiuza CR, Bressan E, Claudino RF, Leite DF, Rae GA. Endothelins as pronociceptive mediators of the rat trigeminal system: role of ETA and ETB receptors. Brain Res. 2010;1345:73-83.
35. Berti-Mattera LN, Gariepy CE, Burke RM, Hall AK. Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetes. Exp Neurol. 2006;201(2):399-406.
36. Plant TD, Zöllner C, Kepura F, et al. Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C. Mol Pain. 2007;3(1):35.
37. Giaid A, Gibson SJ, Ibrahim BN, et al. Endothelin-1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci U S A. 1989;86(19): 7634-7638.
38. Feng B, Strichartz G. Endothelin-1 raises excitability and reduces potassium currents in sensory neurons. Brain Res Bull. 2009;79(6): 345-350.
39. Houck CS, Khodorova A, Reale AM, Strichartz GR, Davar G. Sensory fibers resistant to the actions of tetrodotoxin mediate nocifensive responses to local administration of endothelin-1 in rats. Pain. 2004;110(3):719-726.
40. Cardenas LM, Cardenas CG, Scroggs RS. 5HT increases excitability of nociceptor-like rat dorsal root ganglion neurons via cAMP-coupled TTX-resistant Na(+) channels. J Neurophysiol. 2001;86(1): 241-248.
41. Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertermous T. Expression of the potent vasoconstrictor endothelin in the human central nervous system. J Clin Invest. 1990;86(1):141-147.
42. Giaid A, Gibson SJ, Herrero MT, et al. Topographical localisation of endothelin mRNA and peptide immunoreactivity in neurones of the human brain. Histochemistry. 1991;95(3):303-314.
43. Yoshizawa T, Kimura S, Kanazawa I, Uchiyama Y, Yanagisawa M, Masaki T. Endothelin localizes in the dorsal horn and acts on the spinal neurones: possible involvement of dihydropyridine-sensitive calcium channels and substance P release. Neurosci Lett. 1989;102(2-3): 179-184.
44. Kurokawa K, Yamada H, Ochi J. Topographical distribution of neurons containing endothelin type A receptor in the rat brain. J Comp Neurol. 1997;389(2):348-360.
45. Yamada H, Kurokawa K. Histochemical studies on endothelin and the endothelin-A receptor in the hypothalamus. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S215-S218.
46. Ferreira SH, Romitelli M, de Nucci G. Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol. 1989;13(Suppl 5):S220-S222.
47. Raffa RB, Jacoby HI. Endothelin-1, -2 and -3 directly and big-endothelin-1 indirectly elicit an abdominal constriction response in mice. Life Sci. 1991;48(17):PL85-PL90.
48. Raffa RB, Schupsky JJ, Martinez RP, Jacoby HI. Endothelin-1-induced nociception. Life Sci. 1991;49(11):PL61-PL65.
49. Hans G, Deseure K, Robert D, De Hert S. Neurosensory changes in a human model of endothelin-1 induced pain: a behavioral study. Neurosci Lett. 2007;418(2):117-121.
50. Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G. Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci. 2001;21(14):5358-5366.
51. Namer B, Hilliges M, Orstavik K, et al. Endothelin-1 activates and sensitizes human C-nociceptors. Pain. 2008;137(1):41-49.
52. Piovezan AP, D'Orléans-Juste P, Tonussi CR, Rae GA. Endothelins potentiate formalin-induced nociception and paw edema in mice. Can J Physiol Pharmacol. 1997;75(6):596-600.
53. D'Amico M, Di Filippo C, Rossi F. Selective and non-selective ET antagonists reveal an ET(A)/ET(B) receptor mediated ET-1-induced antinociceptive effect in PAG area of mice. Life Sci. 1997;61(25):PL 397-PL 401.
54. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol. 2003;89(5): 2441-2448.
55. Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G. Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport. 1998;9(10):2279-2283.
56. Khodorova A, Strichartz GR. Contralateral paw sensitization following injection of endothelin-1: effects of local anesthetics differentiate peripheral and central processes. Neuroscience. 2010;165(2): 553-560.
57. Raffa RB, Schupsky JJ, Jacoby HI. Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther. 1996;276(2):647-651.
58. Piovezan AP, D'Orléans-Juste P, Souza GE, Rae GA. Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol. 2000;129(5):961-968.
59. Khodorova A, Fareed MU, Gokin A, Strichartz GR, Davar G. Local injection of a selective endothelin-B receptor agonist inhibits endothelin-1-induced pain-like behavior and excitation of nociceptors in a naloxone-sensitive manner. J Neurosci. 2002;22(17): 7788-7796.
60. Menéndez L, Lastra A, Hidalgo A, Baamonde A. Nociceptive reaction and thermal hyperalgesia induced by local ET-1 in mice: a behavioral and Fos study. Naunyn Schmiedebergs Arch Pharmacol. 2003;367(1):28-34.
61. McKelvy AD, Mark TR, Sweitzer SM. Age- and sex-specific nociceptive response to endothelin-1. J Pain. 2007;8(8):657-666.
62. Shrestha S, Gracias NG, Mujenda F, Khodorova A, Vasko MR, Strichartz GR. Local antinociception induced by endothelin-1 in the hairy skin of the rat's back. J Pain. 2009;10(7):702-714.
63. Gomes LO, Hara DB, Rae GA. Endothelin-1 induces itch and pain in the mouse cheek model. Life Sci Mar. 2012;91(13-14):628-633.
64. Khodorova A, Navarro B, Jouaville LS, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med. 2003;9(8):1055-1061.
65. da Cunha JM, Rae GA, Ferreira SH, Cunha FQ. Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. Eur J Pharmacol. 2004;501(1-3): 87-94.
66. Motta EM, Calixto JB, Rae GA. Mechanical hyperalgesia induced by endothelin-1 in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood). 2006;231(6):1141-1145.
67. Baamonde A, Lastra A, Villazón M, Bordallo J, Hidalgo A, Menéndez L. Involvement of endogenous endothelins in thermal and mechanical inflammatory hyperalgesia in mice. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(2):245-251.
68. Verri WA Jr, Schivo IR, Cunha TM, Liew FY, Ferreira SH, Cunha FQ. Interleukin-18 induces mechanical hypernociception in rats via endothelin acting on ETB receptors in a morphine-sensitive manner. J Pharmacol Exp Ther. 2004;310(2):710-717.
69. Khodorova A, Richter J, Vasko MR, Strichartz G. Early and late contributions of glutamate and CGRP to mechanical sensitization by endothelin-1. J Pain. 2009;10(7):740-749.
70. Kawamata T, Ji W, Yamamoto J, Niiyama Y, Furuse S, Namiki A. Contribution of transient receptor potential vanilloid subfamily 1 to endothelin-1-induced thermal hyperalgesia. Neuroscience. 2008;154(3):1067-1076.
71. Motta EM, Chichorro JG, D'Orléans-Juste P, Rae GA. Roles of endothelin ETA and ETB receptors in nociception and chemical, thermal and mechanical hyperalgesia induced by endothelin-1 in the rat hindpaw. Peptides. 2009;30(5):918-925.
72. Stösser S, Agarwal N, Tappe-Theodor A, Yanagisawa M, Kuner R. Dissecting the functional significance of endothelin A receptors in peripheral nociceptors in vivo via conditional gene deletion. Pain. 2010;148(2):206-214.
73. Plant TD, Zöllner C, Mousa SA, Oksche A. Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor. Exp Biol Med (Maywood). 2006;231(6):1161-1164.
74. Yamamoto H, Kawamata T, Ninomiya T, Omote K, Namiki A. Endothelin-1 enhances capsaicin-evoked intracellular Ca2+ response via activation of endothelin a receptor in a protein kinase Cepsilon-dependent manner in dorsal root ganglion neurons. Neuroscience. 2006;137(3):949-960.
75. Piovezan AP, D'Orléans-Juste P, Tonussi CR, Rae GA. Effects of endothelin-1 on capsaicin-induced nociception in mice. Eur J Pharmacol. 1998;351(1):15-22.
76. Smith T, Beasley S, Smith S, Mark I, Sweitzer SM. Endothelin-1-induced priming to capsaicin in young animals. Neurosci Lett. 2014;567:15-18.
77. Mujenda FH, Duarte AM, Reilly EK, Strichartz GR. Cutaneous endothelin-A receptors elevate post-incisional pain. Pain. 2007; 133(1-3):161-173.
78. Kamei J, Hitosugi H, Kawashima N, Misawa M, Kasuya Y. Antinociceptive effects of intrathecally administered endothelin-1 in mice. Neurosci Lett. 1993;153(1):69-72.
79. Yamamoto T, Shimoyama N, Asano H, Mizuguchi T. Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, an endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist. J Pharmacol Exp Ther. 1994;271(1):156-163.
80. Hung VK, Chen SM, Tai LW, Chen AY, Chung SK, Cheung CW. Over-expression of endothelin-1 in astrocytes, but not endothelial cells, ameliorates inflammatory pain response after formalin injection. Life Sci. 2012;91(13-14):618-622.
81. D'Amico M, Berrino L, Maione S, Filippelli A, de Novellis V, Rossi F. Endothelin-1 in periaqueductal gray area of mice induces analgesia via glutamatergic receptors. Pain. 1996;65(2-3):205-209.
82. Hasue F, Kuwaki T, Yamada H, Fukuda Y, Shimoyama M. Inhibitory actions of endothelin-1 on pain processing. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S318-S320.
83. Ergul A, Shoemaker K, Puett D, Tackett RL. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther. 1998;285(2):511-517.
84. Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin levels in healthy children: high values in early infancy. J Cardiovasc Pharmacol. 1991;17(Suppl 7):S404-S405.
85. Giannessi D, Del Ry S, Andreassi MG, et al. High density of endothelin binding sites in the hearts of infants and children. Life Sci. 1999;64(8):697-705.
86. Joseph EK, Levine JD. Sexual dimorphism in endothelin-1 induced mechanical hyperalgesia in the rat. Exp Neurol. 2012;233(1): 505-512.
87. McKelvy AD, Sweitzer SM. Endothelin-1 exposure on postnatal day 7 alters expression of the endothelin B receptor and behavioral sensitivity to endothelin-1 on postnatal day 11. Neurosci Lett. 2009;451(1):89-93.
88. Cui P, Tani K, Kitamura H, et al. A novel bioactive 31-amino acid endothelin-1 is a potent chemotactic peptide for human neutrophils and monocytes. J Leukoc Biol. 2001;70(2):306-312.
89. Miyasaka N, Hirata Y, Ando K, et al. Increased production of endothelin-1 in patients with inflammatory arthritides. Arthritis Rheum. 1992;35(4):397-400.
90. Khodorova A, Zou S, Ren K, Dubner R, Davar G, Strichartz G. Dual Roles for Endothelin-B Receptors in Modulating Adjuvant-Induced Inflammatory Hyperalgesia in Rats. Open Pain J. 2009;2(1):30-40.
91. De-Melo JD, Tonussi CR, D'Orléans-Juste P, Rae GA. Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain. 1998;77(3):261-269.
92. De-Melo JD, Tonussi CR, D'Orléans-Juste P, Rae GA. Effects of endothelin-1 on inflammatory incapacitation of the rat knee joint. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S518-S520.
93. Imhof AK, Glück L, Gajda M, Bräuer R, Schaible HG, Schulz S. Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice. Arthritis Res Ther. 2011;13(3):R97.
94. Piovezan AP, D'Orléans-Juste P, Frighetto M, Souza GE, Henriques MG, Rae GA. Endothelins contribute towards nociception induced by antigen in ovalbumin-sensitised mice. Br J Pharmacol. 2004;141(4):755-763.
95. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44(1): 77-87.
96. Quang PN, Schmidt BL. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain. 2010;149(2):254-262.
97. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med. 2001;2(1):24-27.
98. Yuyama H, Koakutsu A, Fujiyasu N, et al. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol. 2004;44(Suppl 1):S479-S482.
99. Hamamoto DT, Khasabov SG, Cain DM, Simone DA. Tumor-evoked sensitization of C nociceptors: a role for endothelin. J Neurophysiol. 2008;100(4):2300-2311.
100. Pickering V, Jay Gupta R, Quang P, Jordan RC, Schmidt BL. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain. 2008;12(3):293-300.
101. Wacnik PW, Eikmeier LJ, Ruggles TR, et al. Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci. 2001;21(23):9355-9366.
102. Peters CM, Lindsay TH, Pomonis JD, et al. Endothelin and the tumorigenic component of bone cancer pain. Neuroscience. 2004;126(4): 1043-1052.
103. Schmidt BL, Pickering V, Liu S, et al. Peripheral endothelin A receptor antagonism attenuates carcinoma-induced pain. Eur J Pain. 2007;11(4):406-414.
104. Fujita M, Andoh T, Saiki I, Kuraishi Y. Involvement of endothelin and ET(A) endothelin receptor in mechanical allodynia in mice given orthotopic melanoma inoculation. J Pharmacol Sci. 2008;106(2): 257-263.
105. Baamonde A, Lastra A, Fresno MF, et al. Implantation of tumoral XC cells induces chronic, endothelin-dependent, thermal hyperalgesia in mice. Cell Mol Neurobiol. 2004;24(2):269-281.
106. Tada H, Muramatsu I, Nakai T, Kigoshi S, Miyabo S. Effects of chronic diabetes on the responsiveness to endothelin-1 and other agents of rat atria and thoracic aorta. Gen Pharmacol. 1994;25(6):1221-1228.
107. Jarvis MF, Wessale JL, Zhu CZ, et al. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol. 2000;388(1): 29-35.
108. Kamei J, Hitosugi H, Kawashima N, Misawa M, Kasuya Y. Effects of diabetes on the antinociceptive effects of intrathecally administered endothelin-1. Res Commun Chem Pathol Pharmacol. 1993;79(2): 209-217.
109. Chichorro JG, Zampronio AR, Rae GA. Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain. Exp Biol Med (Maywood). 2006;231(6):1136-1140.
110. Chichorro JG, Zampronio AR, Souza GE, Rae GA. Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. Pain. 2006;123(1-2):64-74.
111. Millecamps M, Laferrière A, Ragavendran JV, Stone LS, Coderre TJ. Role of peripheral endothelin receptors in an animal model of complex regional pain syndrome type 1 (CRPS-I). Pain. 2010;151(1):174-183.
112. Klass M, Hord A, Wilcox M, Denson D, Csete M. A role for endothelin in neuropathic pain after chronic constriction injury of the sciatic nerve. Anesth Analg. 2005;101(6):1757-1762.
113. Werner MF, Trevisani M, Campi B, André E, Geppetti P, Rae GA. Contribution of peripheral endothelin ETA and ETB receptors in neuropathic pain induced by spinal nerve ligation in rats. Eur J Pain. 2010;14(9):911-917.
114. Raffa RB, Schupsky JJ, Lee DK, Jacoby HI. Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther. 1996;278(1):1-7.
115. Griswold DE, Douglas SA, Martin LD, et al. Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol. 1999;56(4):807-812.
116. Zagorodnyuk VP, Kyloh M, Nicholas S, et al. Loss of visceral pain following colorectal distension in an endothelin-3 deficient mouse model of Hirschsprung's disease. J Physiol. 2011;589(Pt 7):1691-1706.
117. Kanazawa S, Tsunoda T, Onuma E, Majima T, Kagiyama M, Kikuchi K. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96(3):822-828.
118. Murch SH, Braegger CP, Sessa WC, MacDonald TT. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. Lancet. 1992;339(8790):381-385.
119. Letizia C, Boirivant M, De Toma G, et al. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis. Ital J Gastroenterol Hepatol. 1998;30(3):266-269.
120. Shiu YT, McIntire LV, Udden MM. Sickle erythrocytes increase prostacyclin and endothelin-1 production by cultured human endothelial cells under flow conditions. Eur J Haematol. 2002;68(3):163-169.
121. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest. 1995;96(2):1145-1151.
122. Hammerman SI, Kourembanas S, Conca TJ, Tucci M, Brauer M, Farber HW. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 1997;156(1): 280-285.
123. Tharaux PL, Hagège I, Placier S, et al. Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrol Dial Transplant. 2005;20(11):2408-2413.
124. Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92(7):2551-2555.
125. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. 2004;76(3):245-251.
126. Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood. 1998;92(7):2594-2596.
127. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 2003;3(4): 215-226.
128. Odièvre MH, Brun M, Krishnamoorthy R, Lapouméroulie C, Elion J. Sodium phenyl butyrate downregulates endothelin-1 expression in cultured human endothelial cells: relevance to sickle-cell disease. Am J Hematol. 2007;82(5):357-362.
129. Lapouméroulie C, Benkerrou M, Odièvre MH, Ducrocq R, Brun M, Elion J. Decreased plasma endothelin-1 levels in children with sickle cell disease treated with hydroxyurea. Haematologica. 2005;90(3):401-403.
130. De Franceschi L, Platt OS, Malpeli G, et al. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J. 2008;22(6):1849-1860.
131. Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118(5): 1924-1933.
132. Schlenz AM, McClellan CB, Mark TR, et al. Sensitization to acute procedural pain in pediatric sickle cell disease: modulation by painful vaso-occlusive episodes, age, and endothelin-1. J Pain. 2012;13(7):656-665.
133. Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood. 2002;99(1):357-603.
134. Benza RL. Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung. 2008;186(4):247-254.
135. Rivera A. Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists. Am J Physiol Cell Physiol. 2007;293(3):C960-C966.
136. Chaar V, Tarer V, Etienne-Julan M, Diara JP, Elion J, Romana M. ET-1 and ecNOS gene polymorphisms andsusceptibility to acute chest syndrome and painful vaso-occlusive crises in children with sickle cell anemia. Haematologica. 2006;91(9):1277-1278.
137. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Free Radic Biol Med. 2004;36(6):707-717.
138. Morris CR, Gladwin MT, Kato GJ. Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med. 2008;8(7):620-632.
139. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med. 2008;44(8): 1506-1528.
140. Bhalla S, Matwyshyn G, Gulati A. Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists. Brain Res. 2005;1064(1-2):126-135.
141. Matwyshyn GA, Bhalla S, Gulati A. Endothelin ETA receptor blockade potentiates morphine analgesia but does not affect gastrointestinal transit in mice. Eur J Pharmacol. 2006;543(1-3):48-53.
142. Selenko-Gebauer N, Duschek N, Minimair G, Stingl G, Karlhofer F. Successful treatment of patients with severe secondary Raynaud's phenomenon with the endothelin receptor antagonist bosentan. Rheumatology (Oxford). 2006;45(Suppl 3):iii45-iii48.
143. Naprawa JT, Bonsu BK, Goodman DG, Ranalli MA. Serum biomarkers for identifying acute chest syndrome among patients who have sickle cell disease and present to the emergency department. Pediatrics. 2005;116(3):e420-e425.
144. Munts AG, Zijlstra FJ, Nibbering PH, et al. Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia. Clin J Pain. 2008;24(1):30-34.
145. Dhaun N, Webb DJ. Endothelin-receptor antagonism: the future is bright. Lancet. 2008;371(9630):2061-2062.
146. Griswold DE, Douglas SA, Martin LD, et al. Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice. J Cardiovasc Pharmacol. 2000;36(5)(Suppl 1):S78-S81.
147. Cain DM, Wacnik PW, Eikmeier L, Beitz A, Wilcox GL, Simone DA. Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med. 2001;2(1):15-23.